Central Medical Procurement Authority Act 2023Section 22
22. Competitive negotiations
(1) The Authority may engage in competitive negotiations for
the procurement of a medical supply from suppliers where –
(a) there is an urgent need for the procurement of
the medical supply and engaging in any other
method of procurement would be impractical and
time-consuming, provided that the circumstances
giving rise to the urgency were not foreseeable by the
Authority or was not the result of any dilatory conduct
on the part of the Authority;
(b) due to a catastrophe, there is an urgent need for the
procurement of the medical supply and engaging in any
other method of procurement would be impractical and
time-consuming;
(c) all the bids received from the open competitive bidding
or restricted bidding procurement method are classed
as irregular or unacceptable;
(d) the Authority determines that the use of any other
method of procurement is not appropriate for the
interests of Mauritius; or
(e) it is required as a complementary procedure as –
(i) there is a tie in the lowest evaluated price by 2 or
more bidders;
(ii) there is a tie in the highest combined score
points; or
(iii) the lowest evaluated price substantially exceeds
the estimated cost.
(2) For the purpose of subsection (1)(e), the Authority shall
identify –
(a) the bidders affected by the tie; or
(b) the bidders who quoted prices which are substantially
above the estimated cost.
116 Acts 2023
(3) Where a bidder has quoted above the above estimated cost,
the Authority shall –
(a) reveal the estimated cost to the bidder; and
(b) limit its invitation to bidders whose evaluated prices
are not more than the prescribed thresholds.
(4) In subsection (1)(c) –
“irregular”, in relation to a bid, means that –
(a) the bid does not comply with the bidding documents;
(b) there is evidence of collusion or corruption; or
(c) the bid is abnormally low;
“unacceptable”, in relation to a bid, means that –
(a) the bid was submitted by a bidder who does not have
the required qualifications; or
(b) the price quoted substantially exceeds the updated cost
estimate.